...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.
【24h】

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

机译：口服抗高血糖药物对2型糖尿病患者血清脂质谱的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: Patients with type 2 diabetes often have dyslipidaemia, putting them at risk of cardiovascular disease, and are frequently treated with oral anti-hyperglycaemic medications (OAMs). This review compares the effects of OAMs on serum lipids [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and free fatty acids (FFAs)] in patients with type 2 diabetes. METHODS: medline was searched for entries indexed from January 1966 to November 2002; search terms included the names of OAMs and serum lipids, limited to English language and human subjects. We selected clinical studies in type 2 diabetes of OAM monotherapy that included serum lipid data, treated all patients in a treatment group with the same drug, used therapeutic OAM doses not higher than the maximum recommended in the USA, compared therapy with baseline or placebo and specified statistical tests used. One unblinded investigator selected studies for inclusion. Datareported include number of patients, study length, OAM dose, serum lipid data at baseline and endpoint, p-values and statistical tests. RESULTS: Data on the serum lipid effects of sulphonylureas, repaglinide, nateglinide and miglitol were inconclusive. Acarbose increased HDL-C and decreased LDL-C and voglibose reduced TC. Metformin at higher doses reduced TC; data on its effects on other lipids were inconclusive. Rosiglitazone increased LDL-C, HDL-C and TC and reduced FFAs but had no effect on TGs. Pioglitazone increased HDL-C and reduced TGs and FFAs but did not affect LDL-C or TC. CONCLUSIONS: Lipid changes as a result of improved glycaemic control are not uniform findings associated with anti-diabetic therapy. Only metformin, acarbose, voglibose, rosiglitazone and pioglitazone had significant effects on the lipid profile. These effects should be considered when selecting OAMs for patients with type 2 diabetes.
机译：目的：2型糖尿病患者经常患有血脂异常，使他们有患心血管疾病的风险，并经常接受口服抗高血糖药物（OAM）的治疗。这篇综述比较了OAMs对血脂[总胆固醇（TC），低密度脂蛋白胆固醇（LDL-C），高密度脂蛋白胆固醇（HDL-C），甘油三酸酯（TGs）和游离脂肪酸（FFA）的影响。 ] 2型糖尿病患者。方法：搜索medline以检索1966年1月至2002年11月之间索引的条目。搜索词包括OAM和血清脂质的名称，仅限于英语和人类受试者。我们选择了OAM单药治疗2型糖尿病的临床研究，其中包括血清脂质数据，治疗组中所有患者使用相同药物治疗，使用的OAM治疗剂量不高于美国建议的最高剂量，将治疗与基线或安慰剂比较以及指定的统计检验。一名不知情的研究者选择了纳入研究。报告的数据包括患者人数，研究时间，OAM剂量，基线和终点的血脂数据，p值和统计检验。结果：关于磺脲类，瑞格列奈，那格列奈和米格列醇的血脂影响的数据尚无定论。阿卡波糖增加HDL-C，降低LDL-C，伏格列波糖降低TC。高剂量的二甲双胍可降低TC;其对其他脂质的作用的数据尚无定论。罗格列酮增加LDL-C，HDL-C和TC并降低FFA，但对TG没有影响。吡格列酮增加HDL-C并降低TG和FFA，但不影响LDL-C或TC。结论：改善血糖控制导致的脂质变化与抗糖尿病治疗相关的发现不一致。只有二​​甲双胍，阿卡波糖，伏格列波糖，罗格列酮和吡格列酮对脂质谱有显着影响。在为2型糖尿病患者选择OAM时应考虑这些影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号